FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Described is a group of inventions, comprising a dual-targeted antibody which specifically binds to VEGF and DLL4, a polynucleotide encoding said antibody, an expression vector, which includes a polynucleotide, a transformed CHO cell for expressing said antibody, a method for producing said antibody, a pharmaceutical composition for treating cancer, comprising a therapeutic effective amount of an antibody, a composition for diagnosing cancer, a method for diagnosing cancer and a method of treating cancer, comprising a step of administering said antibody. In one embodiment, the antibody specifically binds to the conformational epitope DLL4, containing amino acid residues from 58th to 65th and from 110th to 115th amino acid sequence of the DLL4 protein shown in SEQ ID NO: 21, which specifically binds to VEGF.
EFFECT: invention widens the range of antibodies binding to VEGF and DLL4.
17 cl, 12 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| ANTI-VEGF/DLL4-IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | 2013 |
|
RU2636043C2 |
| ANTI-VEGF-ANTIBODY AND ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION, DIAGNOSTICS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE | 2014 |
|
RU2644245C2 |
| AGENTS LINKING FRIZZLED RECEPTOR AND THEIR USE | 2009 |
|
RU2579897C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| HUMAN NOTCH4 ANTIBODY | 2016 |
|
RU2720280C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| POLYSPECIFIC ANTIBODIES | 2009 |
|
RU2547596C2 |
